Strategic Development of CART therapies for the treatment of Hematological and Solid Tumors

Adoptive cell therapy with T lymphocytes genetically modified for the expression of chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for cancer treatment.

However, despite the great expectation that CAR-T cells are generating for the treatment of some hematological malignancies, so far, only five of these products have received approval for use in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma. 

The SOCRATHeS project aims to advance the development of a key technological platform for implementing CAR-T cell-based antitumor therapies in Navarra.  The results of the previous strategic project, the DESCARTHeS project, have allowed the development of several candidates to advance towards clinical trials for treating AML or hepatocarcinoma, cholangiocarcinoma, or pancreatic cancer. New intellectual property has been generated that protects the use of these new candidates.

Therefore, the first objective of this project is to continue advancing these candidates towards the clinic, performing an exhaustive study to rule out toxicities and confirm their efficacy in relevant tumor models. In turn, this project aims to establish a platform to facilitate the future development of new CAR-Ts for other hematological malignancies and gastrointestinal cancers.

This research is funded by the Government of Navarra for strategic R&D projects. It is coordinated by the Cima Universidad de Navarra (FIMA) and includes the Clínica Universidad de Navarra, the Hospital Universitario de Navarra, and the Navarra companies Recombina Biotech and 3P Biopharmaceuticals.

Need more information?

If you are interested in learning more about our research, please contact us.

Coordinator and partners

Project coordinator: 

  • FIMA through Cima Universidad de Navarra

Project partners:

  • Clínica Universidad de Navarra
  • Navarra Hospital Complex
  • Recombina Biotech
  • 3P Biopharmaceuticals

Objectives of the  SOCRATHeS consortium

Specialized teams to achieve the objective

Identification of therapeutic targets

for the development of CARTs in hematological and gastrointestinal tumors.

Development of new CARTs designs

pto increase the efficacy, survival, persistence, and safety of CART cell therapy.

Development and use of preclinical
predictive models

to assess the therapeutic efficacy and safety of CAR-Ts

of the manufacturing

manufacturing, fabrication and transportation of CARTs for clinical use.

Icono equipo profesionales Project participants

  • Juan José Lasarte
  • Teresa Lozano
  • Sandra Hervás
  • Flor Navarro
  • Patricia Sarrión
  • Juan Roberto Rodríguez Madoz
  • Rebeca Martínez Turrillas
  • Amaia Vilas
  • Patxi San Martín
  • Antonio Pineda Lucena
  • Noelia Casares
  • Elizabeth Guruceaga
  • María Calleja Cervantes
  • Felipe Prósper
  • Susana Inogés
  • Ascensión López-Díaz de Cerio
  • Cristina Calviño
  • Ana Margarita Redondo
  • Mª Cruz Viguria Alegría
  • Mª Luisa Antelo Caamaño
  • Pablo Rodríguez Wilhemi
  • Hugo Arasanz
  • María Alsina
  • Olga Morejón
  • Verónica Fernández
  • Carlos López
  • David Villanueva
  • Íñigo Sarobe
  • Jania Suárez
  • Andrés Guerrero
  • Mçonica Tormo
  • María Manuela Peñas
  • Cristina Perpiñá Viciano
  • Leire García